Practical Geriatrics ›› 2022, Vol. 36 ›› Issue (10): 991-995.doi: 10.3969/j.issn.1003-9198.2022.10.005
Previous Articles Next Articles
Received:2022-06-08
Online:2022-10-20
Published:2022-10-21
CLC Number:
| [1] SUN H, SAEEDI P, KARURANGA S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 [J]. Diabetes Res Clin Pract, 2022, 183: 109119. [2] HOLMAN N, YOUNG B, GADSBY R. Current prevalence of type 1 and type 2 diabetes in adults and children in the UK [J]. Diabet Med, 2015, 32(9): 1119-1120. [3] 中国老年2型糖尿病防治临床指南编写组, 中国老年医学学会老年内分泌代谢分会, 中国老年保健医学研究会老年内分泌与代谢分会, 等. 中国老年2型糖尿病防治临床指南(2022年版)[J]. 中华内科杂志, 2022, 61(1): 12-50. [4] DA ROCHA FERNANDES J, OGURTSOVA K, LINNENKAMP U, et al. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes [J]. Diabetes Res Clin Pract, 2016, 117: 48-54. [5] SCHELLENBERG E S, DRYDEN D M, VANDERMEER B, et al. Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis [J]. Ann Intern Med, 2013, 159(8): 543-551. [6] BOOTH G L, KAPRAL M K, FUNG K, et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study [J]. Lancet, 2006, 368(9529): 29-36. [7] BECKMAN J A, PANENI F, COSENTINO F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II [J]. Eur Heart J, 2013, 34(31): 2444-2452. [8] PARRY H M, DESHMUKH H, LEVIN D, et al. Both high and low HbA1c predict incident heart failure in type 2 diabetes mellitus [J]. Circ Heart Fail, 2015, 8(2): 236-242. [9] CHEN A, WANG H, SU Y, et al. Exosomes: biomarkers and therapeutic targets of diabetic vascular complications [J]. Front Endocrinol: Lausanne, 2021, 12: 720466. [10] SUN Y, SHI H, YIN S, et al. Human mesenchymal stem cell derived exosomes alleviate type 2 diabetes mellitus by reversing peripheral insulin resistance and relieving beta-cell destruction [J]. ACS Nano, 2018, 12(8): 7613-7628. [11] MULLER-WIELAND D, KELLERER M, CYPRYK K, et al. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes [J]. Diabetes Obes Metab, 2018, 20(11): 2598-2607. [12] GROUP A S C, BOWMAN L, MAFHAM M, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus [J]. N Engl J Med, 2018, 379(16): 1529-1539. [13] 孙敏, 张冬颖. 钠-葡萄糖共转运蛋白2抑制剂对2型糖尿病患者心血管保护作用的研究进展 [J]. 上海交通大学学报(医学版), 2021, 41(3): 391-395. [14] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)(下) [J]. 中国实用内科杂志, 2021, 41(9): 757-784. [15] 王富军. 中国糖尿病足防治指南(2019版)解读 [J]. 河北医科大学学报, 2019, 40(11): 1241-1250. [16] PANENI F, BECKMAN J A, CREAGER M A, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I [J]. Eur Heart J, 2013, 34(31): 2436-2443. [17] SELVIN E, CORESH J, BRANCATI F L. The burden and treatment of diabetes in elderly individuals in the U.S [J]. Diabetes Care, 2006, 29(11): 2415-2419. [18] MARTINEZ-CASTELAO A, NAVARRO-GONZALEZ J F, GORRIZ J L, et al. The concept and the epidemiology of diabetic nephropathy have changed in recent years [J]. J Clin Med, 2015, 4(6): 1207-1216. [19] VAN DIEREN S, BEULENS J W, VAN DER SCHOUW Y T, et al. The global burden of diabetes and its complications: an emerging pandemic [J]. Eur J Cardiovasc Prev Rehabil, 2010, 17(Suppl 1): S3-S8. [20] DONATE-CORREA J, LUIS-RODRÍGUEZ D, MARTÍN-NÚÑEZ E, et al. Inflammatory targets in diabetic nephropathy [J]. J Clin Med, 2020, 9(2):458. [21] PUGLIESE G, PENNO G, NATALI A, et al. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function" [J]. J Nephrol, 2020, 33(1): 9-35. [22] KIM M K. Treatment of diabetic kidney disease: current and future targets [J]. Korean J Intern Med, 2017, 32(4): 622-630. [23] DAVID F, SILVIO E, CHRISTOPHER P, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME Trial[J]. Circulation, 2019, 139(11):1384-1395. [24] ZOUNGAS S, CHALMERS J, NINOMIYA T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds [J]. Diabetologia, 2012, 55(3): 636-643. [25] ROETT M A, LIEGL S, JABBARPOUR Y. Diabetic nephropathy-the family physician's role [J]. Am Fam Physician, 2012, 85(9): 883-889. [26] UMANATH K, LEWIS J B. Update on diabetic nephropathy: core curriculum 2018 [J]. Am J Kidney Dis, 2018, 71(6): 884-895. [27] ARORA M K, SINGH U K. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update [J]. Vascul Pharmacol, 2013, 58(4): 259-271. [28] SAKLAYEN M G, GYEBI L K, TASOSA J, et al. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial [J]. J Investig Med, 2008, 56(4): 714-719. [29] GUILLAUME J, JEAN C, CHARLES C.Vitamin D in chronic kidney disease and dialysis patients[J]. Nutrients, 2017, 9(4):328. [30] DE ZEEUW D, RENFURM R W, BAKRIS G, et al. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial [J]. Lancet Diabetes Endocrinol, 2018, 6(12): 925-933. [31] KLEIN R, KLEIN B E, MOSS S E. Visual impairment in diabetes [J]. Ophthalmology, 1984, 91(1): 1-9. [32] 阚芳芳, 方福生, 孙般诺, 等. 不同发病年龄老年2型糖尿病的临床特点[J]. 中华保健医学杂志, 2015, 17(5): 360-363. [33] 高晔, 孙桂波, 罗云, 等. 糖尿病视网膜病的发病机制及药物干预研究进展[J]. 中国药理学通报, 2020, 36(4): 491-495. [34] KITADA M, KUME S, IMAIZUMI N, et al. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway[J]. Diabetes, 2011, 60(2): 634-643. [35] LIU K, WANG H, HE W, et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study [J]. Br J Ophthalmol, 2021. DOI: 10.1136/BJOPHTHALMOL-2020-318690. [36] POP-BUSUI R, BOULTON A J, FELDMAN E L, et al. Diabetic neuropathy: a position statement by the American Diabetes Association [J]. Diabetes Care, 2017, 40(1): 136-154. [37] TESFAYE S, STEVENS L K, STEPHENSON J M, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study [J]. Diabetologia, 1996, 39(11): 1377-1384. [38] TESFAYE S, CHATURVEDI N, EATON S E, et al. Vascular risk factors and diabetic neuropathy [J]. N Engl J Med, 2005, 352(4): 341-350. [39] CALLAGHAN B C, CHENG H T, STABLES C L, et al. Diabetic neuropathy: clinical manifestations and current treatments [J]. Lancet Neurol, 2012, 11(6): 521-534. [40] TESFAYE S, VILEIKYTE L, RAYMAN G, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management [J]. Diabetes Metab Res Rev, 2011, 27(7): 629-638. [41] JAVED S, PETROPOULOS I N, ALAM U, et al. Treatment of painful diabetic neuropathy [J]. Ther Adv Chronic Dis, 2015, 6(1): 15-28. [42] CHANG M, NGUYEN T T. Strategy for treatment of infected diabetic foot ulcers [J]. Acc Chem Res, 2021, 54(5): 1080-1093. [43] 中华医学会糖尿病学分会神经并发症学组. 糖尿病神经病变诊治专家共识(2021年版) [J]. 国际内分泌代谢杂志, 2021, 41(3): 256-272. [44] BOULTON A J M. The diabetic foot [J]. Medicine, 2019, 47(2): 100-105. [45] BEYAZ S, GULER U O, BAGIR G S. Factors affecting lifespan following below-knee amputation in diabetic patients [J]. Acta Orthop Traumatol Turc, 2017, 51(5): 393-397. [46] JIANG Y, RAN X, JIA L, et al. Epidemiology of type 2 diabetic foot problems and predictive factors for amputation in China [J]. Int J Low Extrem Wounds, 2015, 14(1): 19-27. [47] EIKELBOOM J W, CONNOLLY S J, BOSCH J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease [J]. N Engl J Med, 2017, 377(14): 1319-1330. [48] OKAMOTO S, IIDA O, TAKAHARA M, et al. Impact of perioperative complications after endovascular therapy in diabetic patients with critical limb ischemia due to isolated infrapopliteal lesions [J]. J Endovasc Ther, 2016, 23(2): 371-377. [49] 《多学科合作下糖尿病足防治专家共识》编写组. 多学科合作下糖尿病足防治专家共识(2020版)精华版(Ⅰ) [J]. 中华烧伤杂志, 2020, 36(8): 637-646. [50] FRYKBERG R G, WUKICH D K, KAVARTHAPU V, et al. Surgery for the diabetic foot: a key component of care [J]. Diabetes Metab Res Rev, 2020, 36 (Suppl 1): e3251. |
| [1] | ZHANG Xingxing, ZHANG Haiyang, HE Xiaojing, LU Xiang. Investigation on the relationship between different physical indexes and the risk of diabetes mellitus in the elderly [J]. Practical Geriatrics, 2024, 38(9): 940-943. |
| [2] | ZHAO Yuling, HUANG Jing, YE Wenchun. Interaction effects of serum levels of γ-aminobutyric acid and insulin-like growth factor-1 on cardiovascular event risk in elderly patients with prediabetes [J]. Practical Geriatrics, 2024, 38(8): 816-820. |
| [3] | LIANG Shanshan, LIANG Huan, YANG Shan, LIU Jianfeng. Relationship between sarcopenia and carotid atherosclerosis in elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2024, 38(8): 826-830. |
| [4] | SHI Wen, ZHU Ping, ZHOU Jie, YAN Ting, HUANG Yujie, YAN Yan. Effect of pancreatic kallidinogenase on mild cognitive impairment in elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2024, 38(6): 587-591. |
| [5] | GUO Chun, YI Mengting, ZONG Qianxing, ZHOU Yi, WU Haidi, MO Yongzhen. Development of a 6-month risk prediction model for hypoglycemia in elderly patients with type 2 diabetes mellitus: a longitudinal study [J]. Practical Geriatrics, 2024, 38(6): 592-597. |
| [6] | BAO Hai-tong, TAN Ping, YU Pei-wen, LIU Juan, DING Guo-xian, TONG Qiang-wei, WANG Xiao-dong. Analysis of influencing factors of frailty based on geriatric comprehensive assessment in the elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2022, 36(12): 1264-1268. |
| [7] | CHEN Ming-zhu, XU Qin, CAI Ying-hua. Study on the status and the influencing factors of self-perceived burden in the elderly patients with diabetes mellitus and frailty [J]. Practical Geriatrics, 2022, 36(12): 1269-1272. |
| [8] | . [J]. Practical Geriatrics, 2022, 36(10): 973-977. |
| [9] | . [J]. Practical Geriatrics, 2022, 36(10): 978-982. |
| [10] | . [J]. Practical Geriatrics, 2022, 36(10): 983-985. |
| [11] | . [J]. Practical Geriatrics, 2022, 36(10): 986-990. |
| [12] | YU Yun, TANG Wei, LOU Qing-lin. Clinical characteristics of newly diagnosed type 2 diabetic patients with different age of onset [J]. Practical Geriatrics, 2022, 36(10): 1015-1018. |
| [13] | YAO Zhu-ling, WANG Zhi-yong, XIONG Ya-qing, XU Fei. Epidemiological characteristics of hypertension combined with diabetes among the elderly people in Nanjing, China [J]. Practical Geriatrics, 2022, 36(8): 796-800. |
| [14] | . [J]. Practical Geriatrics, 2022, 36(8): 850-853. |
| [15] | . [J]. Practical Geriatrics, 2022, 36(7): 655-659. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
|
